|
US6773669B1
(en)
|
1995-03-10 |
2004-08-10 |
Maxcyte, Inc. |
Flow electroporation chamber and method
|
|
US6090617A
(en)
|
1996-12-05 |
2000-07-18 |
Entremed, Inc. |
Flow electroporation chamber with electrodes having a crystalline metal nitride coating
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
EP1276865B1
(en)
|
2000-04-28 |
2014-05-21 |
Sangamo BioSciences, Inc. |
Methods for binding an exogenous molecule to cellular chromatin
|
|
US7029916B2
(en)
|
2001-02-21 |
2006-04-18 |
Maxcyte, Inc. |
Apparatus and method for flow electroporation of biological samples
|
|
CA2445260C
(en)
|
2001-04-23 |
2011-02-01 |
Amaxa Gmbh |
Buffer solution for electroporation and a method comprising the use of the same
|
|
AU2002326717A1
(en)
|
2001-08-22 |
2003-03-10 |
Maxcyte, Inc. |
Apparatus and method for electroporation of biological samples
|
|
GB0124391D0
(en)
|
2001-10-11 |
2001-11-28 |
Gene Expression Technologies L |
Control of gene expression
|
|
US20050136040A1
(en)
|
2001-10-11 |
2005-06-23 |
Imperial College Innovations Limited |
Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
|
|
AU2003218382B2
(en)
|
2002-03-21 |
2007-12-13 |
Sangamo Therapeutics, Inc. |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
|
ITMI20030821A1
(it)
|
2003-04-18 |
2004-10-19 |
Internat Ct For Genetic En Gineering And |
Polipeptidi chimerici e loro uso.
|
|
WO2004108883A2
(en)
|
2003-06-10 |
2004-12-16 |
Toolgen, Inc. |
Transducible dna-binding proteins
|
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
|
ES2294757T3
(es)
|
2004-03-15 |
2008-04-01 |
Amaxa Ag |
Recipiente y dispositivo para generar campos electricos en espacios de reaccion individuales.
|
|
KR101301929B1
(ko)
|
2004-05-12 |
2013-09-02 |
맥스시티 인코포레이티드 |
조절된 유동 전기 천공 챔버에 관한 방법 및 장치
|
|
KR100853102B1
(ko)
|
2004-06-12 |
2008-08-21 |
주식회사 디지탈바이오테크놀러지 |
중공구조를 갖는 전기천공 장치
|
|
WO2005123962A2
(en)
|
2004-06-14 |
2005-12-29 |
The University Of Texas At Austin |
Gene targeting in eukaryotic cells by group ii intron ribonucleoprotein particles
|
|
EP1607484B1
(de)
|
2004-06-14 |
2014-04-02 |
Lonza Cologne GmbH |
Verfahren und Schaltungsanordnung zur Behandlung von biologischem Material
|
|
WO2006060409A2
(en)
|
2004-11-30 |
2006-06-08 |
Maxcyte, Inc. |
Computerized electroporation
|
|
US10022457B2
(en)
|
2005-08-05 |
2018-07-17 |
Gholam A. Peyman |
Methods to regulate polarization and enhance function of cells
|
|
DK2341149T3
(en)
|
2005-08-26 |
2017-02-27 |
Dupont Nutrition Biosci Aps |
Use of CRISPR-associated genes (Cas)
|
|
US9428756B2
(en)
|
2006-08-11 |
2016-08-30 |
Dow Agrosciences Llc |
Zinc finger nuclease-mediated homologous recombination
|
|
DK2279253T3
(en)
|
2008-04-09 |
2017-02-13 |
Maxcyte Inc |
Construction and application of therapeutic compositions of freshly isolated cells
|
|
WO2010009252A1
(en)
|
2008-07-18 |
2010-01-21 |
Maxcyte, Inc. |
Methods for optimizing electroporation
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
US9221886B2
(en)
|
2009-04-28 |
2015-12-29 |
President And Fellows Of Harvard College |
Supercharged proteins for cell penetration
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US8956828B2
(en)
*
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
NO2510096T3
(enExample)
|
2009-12-10 |
2015-03-21 |
|
|
|
EP2563918B1
(en)
|
2010-04-26 |
2016-11-23 |
Sangamo BioSciences, Inc. |
Genome editing of a rosa locus using zinc-finger nucleases
|
|
US8876458B2
(en)
|
2011-01-25 |
2014-11-04 |
United Technologies Corporation |
Blade outer air seal assembly and support
|
|
US10391126B2
(en)
|
2011-11-18 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
US20130236504A1
(en)
|
2012-03-06 |
2013-09-12 |
Medical University Of South Carolina |
Delivery System for Enhancing Drug Efficacy
|
|
SI3401400T1
(sl)
|
2012-05-25 |
2019-10-30 |
Univ California |
Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja
|
|
SG11201503059XA
(en)
|
2012-10-23 |
2015-06-29 |
Toolgen Inc |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
EP3138911B1
(en)
|
2012-12-06 |
2018-12-05 |
Sigma Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
CN105658796B
(zh)
|
2012-12-12 |
2021-10-26 |
布罗德研究所有限公司 |
用于序列操纵的crispr-cas组分系统、方法以及组合物
|
|
DK3553174T3
(da)
|
2012-12-17 |
2025-08-04 |
Harvard College |
Rna-guided modificering af humant genom
|
|
WO2014145992A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Adaptive Biotechnologies Corporation |
Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
|
|
US9885033B2
(en)
|
2013-03-15 |
2018-02-06 |
The General Hospital Corporation |
Increasing specificity for RNA-guided genome editing
|
|
AU2014235968B2
(en)
*
|
2013-03-21 |
2018-05-24 |
Ospedale San Raffaele Srl |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
CN105121650A
(zh)
|
2013-04-02 |
2015-12-02 |
拜尔作物科学公司 |
真核生物中的靶向基因组工程
|
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
|
ES2645393T3
(es)
*
|
2013-05-29 |
2017-12-05 |
Cellectis |
Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
WO2015048690A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Optimized small guide rnas and methods of use
|
|
CN110713995B
(zh)
|
2013-10-17 |
2023-08-01 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
|
US9951353B2
(en)
|
2013-11-15 |
2018-04-24 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Engineering neural stem cells using homologous recombination
|
|
JP2017501149A
(ja)
|
2013-12-12 |
2017-01-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
粒子送達構成成分を用いた障害及び疾患の標的化のためのｃｒｉｓｐｒ−ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
IL289736B2
(en)
|
2013-12-12 |
2025-09-01 |
Massachusetts Inst Technology |
Administration, use and therapeutic applications of CRISPR–Cas gene editing systems and gene editing preparations
|
|
CA2933134A1
(en)
|
2013-12-13 |
2015-06-18 |
Cellectis |
Cas9 nuclease platform for microalgae genome engineering
|
|
RU2714404C2
(ru)
|
2014-01-31 |
2020-02-14 |
Фэктор Байосайенс Инк. |
Способы и продукты для получения и доставки нуклеиновых кислот
|
|
WO2015115903A1
(en)
|
2014-02-03 |
2015-08-06 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Site-specific dna break-induced genome editing using engineered nucleases
|
|
EP3800248A3
(en)
|
2014-04-18 |
2021-08-04 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
WO2016036754A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification
|
|
RU2017113134A
(ru)
*
|
2014-09-19 |
2018-10-19 |
Регенерон Фармасьютикалз, Инк. |
Химерные антигенные рецепторы
|
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
|
WO2016057951A2
(en)
|
2014-10-09 |
2016-04-14 |
Life Technologies Corporation |
Crispr oligonucleotides and gene editing
|
|
AU2015339743C1
(en)
|
2014-10-31 |
2021-04-22 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in modified T cells and uses thereof
|
|
WO2016097751A1
(en)
|
2014-12-18 |
2016-06-23 |
The University Of Bath |
Method of cas9 mediated genome engineering
|
|
WO2016118697A1
(en)
|
2015-01-21 |
2016-07-28 |
Phaserx, Inc. |
Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
|
|
US20190388469A1
(en)
|
2015-01-30 |
2019-12-26 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
EP3262173A2
(en)
|
2015-02-23 |
2018-01-03 |
Crispr Therapeutics AG |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
|
US20180298340A1
(en)
|
2015-04-24 |
2018-10-18 |
The Regents Of The University Of California |
Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
|
|
AU2016271147B2
(en)
|
2015-05-29 |
2022-09-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
JP2018518182A
(ja)
|
2015-06-17 |
2018-07-12 |
ザ ユーエービー リサーチ ファンデーション |
ゲノム編集のためのｃｒｉｓｐｒ／ｃａｓ９複合体
|
|
CA2989858A1
(en)
|
2015-06-17 |
2016-12-22 |
The Uab Research Foundation |
Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
|
US20170000743A1
(en)
|
2015-07-02 |
2017-01-05 |
Vindico NanoBio Technology Inc. |
Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
|
|
EP3322297B1
(en)
|
2015-07-13 |
2024-12-04 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
WO2017035659A1
(en)
|
2015-09-01 |
2017-03-09 |
The Hospital For Sick Children |
Method and compositions for removing duplicated copy number variations (cnvs) for genetic disorders and related uses
|
|
CN108137670A
(zh)
*
|
2015-09-09 |
2018-06-08 |
免疫设计股份有限公司 |
Ny-eso-1特异性tcr及其使用方法
|
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
|
US11286480B2
(en)
|
2015-09-28 |
2022-03-29 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
AU2016333898B2
(en)
*
|
2015-10-05 |
2020-11-12 |
Precision Biosciences, Inc. |
Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
|
|
DK3359660T3
(en)
*
|
2015-10-05 |
2020-02-17 |
Prec Biosciences Inc |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
|
WO2017070169A1
(en)
|
2015-10-19 |
2017-04-27 |
The Methodist Hospital |
Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
|
|
WO2017070056A1
(en)
|
2015-10-20 |
2017-04-27 |
10X Genomics, Inc. |
Methods and systems for high throughput single cell genetic manipulation
|
|
WO2017070429A1
(en)
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
|
ES2953925T3
(es)
|
2015-11-04 |
2023-11-17 |
Fate Therapeutics Inc |
Ingeniería genómica de células pluripotentes
|
|
EP4163374A1
(en)
|
2015-11-23 |
2023-04-12 |
The Regents of the University of California |
Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
|
|
AU2016369490C1
(en)
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
JP7449646B2
(ja)
|
2015-12-30 |
2024-03-14 |
アヴェクタス リミテッド |
細胞および組織への遺伝子編集タンパク質および組成物の、ベクターなしでの送達
|
|
CN109311984A
(zh)
|
2016-03-11 |
2019-02-05 |
蓝鸟生物公司 |
基因组编辑的免疫效应细胞
|
|
EP3440191A4
(en)
|
2016-04-07 |
2019-12-11 |
Bluebird Bio, Inc. |
CHIMERIC ANTIGEN RECEPTOR T-CELL COMPOSITIONS
|
|
AU2017250295B2
(en)
|
2016-04-14 |
2022-08-25 |
Fred Hutchinson Cancer Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
SG11201808831TA
(en)
*
|
2016-04-15 |
2018-11-29 |
Memorial Sloan Kettering Cancer Center |
Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
|
|
US11248216B2
(en)
|
2016-04-25 |
2022-02-15 |
The Regents Of The University Of California |
Methods and compositions for genomic editing
|
|
MX388092B
(es)
|
2016-04-29 |
2025-03-19 |
Basf Plant Science Co Gmbh |
Metodos mejorados para la modificacion de acido nucleicos diana.
|
|
EP3463667A1
(en)
|
2016-05-31 |
2019-04-10 |
Massachusetts Institute of Technology |
Hydrodynamically controlled electric fields for high throughput transformation&high throughput parallel transformation platform
|
|
US11713458B2
(en)
|
2016-06-20 |
2023-08-01 |
Octapharma Ag |
Means and methods for modifying multiple alleles
|
|
CN110312799A
(zh)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
新型crispr酶和系统
|
|
WO2018039084A1
(en)
|
2016-08-20 |
2018-03-01 |
The Regents Of The University Of California |
High-throughput system and method for the temporary permeablization of cells
|
|
CA3038839A1
(en)
|
2016-10-12 |
2018-04-19 |
Feldan Bio Inc. |
Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
|
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
EP3541937A4
(en)
|
2016-11-18 |
2020-06-24 |
Christopher Bradley |
REPAIR OF MASSIVELY MULTIPLEXED HOMOLOGICAL TEMPLATE FOR FULL GENERATION
|
|
CA3045131A1
(en)
|
2016-12-14 |
2018-06-21 |
Ligandal, Inc. |
Methods and compositions for nucleic acid and protein payload delivery
|
|
WO2018126205A1
(en)
|
2016-12-30 |
2018-07-05 |
The Regents Of The University Of California |
Methods for selection and generation of genome edited t cells
|
|
US20200362355A1
(en)
|
2017-06-15 |
2020-11-19 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
|
IL274179B2
(en)
*
|
2017-10-27 |
2024-02-01 |
Univ California |
Targeted replacement of endogenous T cell receptors
|
|
BR112020008704A2
(pt)
*
|
2017-10-30 |
2020-11-10 |
Pact Pharma, Inc. |
edição de genes de células primárias
|